reconstitution is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
| Property | Value | Notes |
|---|---|---|
| Primary structure | 28 amino acid residues | N-terminally acetylated |
| Net charge at neutral pH | Negative | Acidic peptide |
| Typical purity assay | Reverse-phase HPLC | UV detection near 214 nm |
| Identity confirmation | Mass spectrometry | Matches expected molecular mass |
| Reconstitution solvent | Sterile water or saline | Follow supplier instructions |
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
=== Geographic distribution === AI activity is heavily concentrated in London and the South East. In 2024, London, the South East, and the East of England accounted for approximately 75% of all registered AI company offices. London has been described by industry investors as "the third largest city in the world for starting AI companies". However, the number of AI firms is growing across all UK regions, with annual growth rates of between 20% and 50%, and at least double the number of AI companies now operating in the West Midlands, North West, East Midlands, Wales, and Yorkshire and Humber compared to 2022.
== Use in dermatology == Mequinol is a common active ingredient in topical drugs used for skin depigmentation. As a topical drug mequinol is often mixed with tretinoin, a topical retinoid. A common formulation for this drug is an ethanolic solution of 2% mequinol and 0.01% tretinoin by mass. Dermatologists commonly prescribe the drug to treat liver spots. Lower dosages of mequinol have been used in conjunction with a Q-switched laser to depigment skin in patients with disseminated idiopathic vitiligo.
Primary sources below are listed at the head of each column, information sourced elsewhere is referenced directly in the relevant cells. Data is for models as marketed in the Japanese domestic market.
Sources: en.wikipedia.org
Narrated by actress Miranda Richardson 27 November Dismantling the Bomb, Pantex in Texas; START II in January 1993; Ted Taylor (physicist); eighteen scientists from the UK worked on the Manhattan Project; the plutonium fissile material, which was half the world's supply, for the July Trinity (nuclear test) was carried on the back seat of a car, to be assembled; the bomb was hoisted on 14 July 1945; a warning flare was fired, then the electrical circuits were connected at 5.29am on 16 July 1945; the bomb was dropped twenty one days later, exploding at 1,900 feet; the Russians developed the bomb through the work of Igor Kurchatov and Yulii Khariton; much American nuclear weapon research also took place at Livermore, California; the first British nuclear test, on 3 October 1952, was set up by two people on HMS Plym; many US weapon cores had been made at the Rocky Flats Plant in Colorado; Viktor Mikhailov (politician), Russian minister of nuclear power; the Nuclear Control Institute. Narrated by Scottish actor Tom Cotcher, produced by Chris Haws, directed by Richard Melman, made by InCA Productions 4 December Electric Skies, about lightning at the Langmuir Laboratory for Atmospheric Research; electrical engineer Martin A.
== Biosynthesis == Proline is biosynthetically derived from the amino acid L-glutamate. Glutamate-5-semialdehyde is first formed by glutamate 5-kinase (ATP-dependent) and glutamate-5-semialdehyde dehydrogenase (which requires NADH or NADPH). This can then either spontaneously cyclize to form 1-pyrroline-5-carboxylic acid, which is reduced to proline by pyrroline-5-carboxylate reductase (using NADH or NADPH), or turned into ornithine by ornithine aminotransferase, followed by cyclisation by ornithine cyclodeaminase to form proline.
=== Skin aging research === There is also ongoing research on topical application of vitamin C to prevent signs of skin aging. Human skin physiologically contains small amounts of vitamin C, which supports collagen synthesis, decreases collagen degradation, and assists in antioxidant protection against UV-induced photo-aging, including photocarcinogenesis. This knowledge is often used as a rationale for the marketing of vitamin C as a topical "serum" ingredient to prevent or treat facial skin aging, melasma (dark pigmented spots), and wrinkles; however, these claims are unsubstantiated and are not supported by research conducted so far; the supposed efficacy of topical treatment as opposed to oral intake is poorly understood. The purported mechanism on supposed benefit of topical vitamin C application to slow skin aging is that vitamin C is an antioxidant, neutralizing free radicals from sunlight exposure, air pollutants or normal metabolic processes. The clinical trial literature is characterized as insufficient to support health claims; one reason being put forward was that "All the studies used vitamin C in combination with other ingredients or therapeutic mechanisms, thereby complicating any specific conclusions regarding the efficacy of vitamin C."
=== Comparison of effects of brimonidine and timolol === A 2013 Cochrane systematic review compared the effect of brimonidine and timolol in slowing the progression of open-angle glaucoma in adult participants. The results showed that participants assigned to brimonidine showed less visual field progression than those assigned to timolol, though the results were not significant, given the heavy loss-to-followup and limited evidence. The mean intraocular pressures for both groups were similar. Participants in the brimonidine group had a higher occurrence of side effects caused by medication than participants in the timolol group.
Sources: en.wikipedia.org
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.
Reverse-phase HPLC separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the expected molecular mass and flags sequence errors. The two techniques are commonly reported together on a certificate of analysis.
Short exposure during handling is not considered a major problem for the dry powder. Prolonged storage at ambient temperature, especially of reconstituted solutions, raises the risk of degradation. Cold storage remains the standard practice for longer periods.
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.